Lupin Signs License and Supply Agreement with Spektus to Commercialise Novel Antidepressant DeslaFlex in Canada

Kiran DSIJCategories: Mindshare, Trending

Join Us Follow UsSelect DSIJ as preferred on

Lupin Signs License and Supply Agreement with Spektus to Commercialise Novel Antidepressant DeslaFlex in Canada

This collaboration significantly strengthens Lupin’s Central Nervous System (CNS) portfolio, providing Canadian patients and healthcare providers with innovative treatment options.

Lupin Limited has entered into a strategic license and supply agreement with Spektus Pharma to commercialise DeslaFlex™, a novel antidepressant, in the Canadian market. Developed using Spektus’s proprietary Flexitab™ oral drug-delivery platform, DeslaFlex™ offers a differentiated formulation designed to improve the management of Major Depressive Disorder (MDD). The partnership leverages Lupin’s extensive commercial infrastructure in Canada alongside Spektus’s specialised capabilities in creating value-added, physician-endorsed CNS therapies.

This collaboration significantly strengthens Lupin’s Central Nervous System (CNS) portfolio, providing Canadian patients and healthcare providers with innovative treatment options. By utilising the Flexitab™ technology, the companies aim to establish a robust platform for future product launches within a supportive regulatory environment. This move underscores Lupin's commitment to expanding its global footprint through high-entry-barrier formulations and strategic speciality partnerships.

Invest where stability meets growth. DSIJ’s Mid Bridge reveals Mid-Cap leaders ready to outperform. Download Detailed Note Here

About Lupin

Lupin Limited is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. Lupin specialises in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Trusted by healthcare professionals and consumers globally, the company enjoys a strong position in India and the U.S. across multiple therapy areas, including respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women's health. Lupin has 15 state-of-the-art manufacturing sites and 7 research centres globally, along with a dedicated workforce of over 24,000 professionals. Lupin is committed to improving patient health outcomes through its subsidiaries - Lupin Diagnostics, Lupin Digital Health, and Lupin Manufacturing Solutions.

How Much Should You Invest Every Month? Click Here to Find Out

Disclaimer: The article is for informational purposes only and not investment advice.